AFP and neoplasm: Univariate analysis of PFS showed that age >60 years, HCV infection, antiviral time >5 years, absence of previous surgery, maximum tumor diameter >5 cm, presence of PVTT and alpha-fetoprotein (AFP) > 200 ng/mL were associated with progression in patients treated with lenvatinib (Table 2).